trending Market Intelligence /marketintelligence/en/news-insights/trending/5h1F2phQjZRnhwSJFznW2w2 content esgSubNav
In This List

Alliance Pharma completes acquisition of TyraTech's head lice treatment

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Alliance Pharma completes acquisition of TyraTech's head lice treatment

Alliance Pharma plc completed its acquisition of the worldwide rights to TyraTech, Inc.'s Vamousse.

TyraTech's shareholders approved the deal on Dec. 27.

Vamousse assets comprise consumer healthcare products for preventing and treating human head lice.